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Systemic sclerosis (SSc) is an inﬂammatory disease of unknown etiology characterized
by widespread organ dysfunction due to ﬁbrosis and ischemia. Its nebulous pathogenic
background and the consequent absence of an etiological therapy prevent the adoption
of satisfying treatment strategies, able to improve patients’ quality of life and survival and
stimulate researchers to identify a unifying pathogenic target. Platelets show a unique bio-
logical behavior, lying at the crossroads between vascular function, innate and adaptive
immunity, and regulation of cell proliferation. Consequently they are also emerging play-
ers in the pathogenesis of many inﬂammatory diseases, including SSc. In the setting of
SSc platelets are detectable in a persistent activated state, which is intimately linked to
the concomitant presence of an injured endothelium and to the widespread activation of
the innate and adaptive immune system. As a consistent circulating source of bioactive
compounds platelets contribute to the development of many characteristic phenomena of
SSc, such as ﬁbrosis and impaired vascular tone.
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PLATELETS, IMMUNITY, AND VESSEL INTEGRITY
Platelets are anucleate cellular fragments emitted by a larger nucle-
ate precursor, the megakaryocyte. Differently from other myeloid
or lymphoid precursors this latter progenitor usually resides in
the bone marrow, but can also be detected in the lung (Kosaki,
2005). During the evolution of the hemopoietic system, platelets
progressively acquired a functional specialization in the control
of vessel integrity and repair (Semple et al., 2011). However, as
probably happened for other circulating innate mediators such
as pentraxins (Manfredi et al., 2008; Martinez de la Torre et al.,
2010), an ancestral link between vessel repair and patrolling
(i.e., between hemostasis and immunity) still seems to charac-
terize platelet biology in humans and “upper” species (Semple
et al., 2011). In the setting of injured vessels, a tripartite net-
work between the endothelium, platelets, and rolling neutrophils
develops (Maugeri et al., 2012). Subsequently extensive physical
and biochemical cross-talks between these cellular species take
place: selectins provide a dual anchorage system to rolling neu-
trophils, since they are both expressed by the endothelium and
by platelets (Maugeri et al., 2012); coagulation factors recruited at
sites of vessel injury also constitute a commonbindingplatform for
leukocytes and platelets (Maugeri et al., 2012); ﬁnally a large array
of membrane-bound and soluble alarmins and immunemediators
(expressed by the endothelium, platelets, and neutrophils) cause
the reciprocal activation of neutrophils and platelets (Maugeri
et al., 2009). Notably, while a platelet–leukocyte network has long
been recognized within the injured vessels, a growing number of
studies is currently elucidating the role of circulating heterotypic
aggregates in vessel biology and inﬂammation (Manfredi et al.,
2010). After engagement of membrane-bound functional Toll-
like receptors, platelets contribute to host defense by favoring
neutrophil activation and NETting (Clark et al., 2007) and shuttle
blood-borne pathogens to immune outposts (such as the spleen),
thus promoting their recognition and clearance by immune cells
(Verschoor et al., 2011). Moreover, although devoid of MHC class
II molecules, platelets express large amounts of membrane-bound
and soluble stimulatory molecules, such as CD154 (Semple et al.,
2011) and in vivo and in vitro studies proved the efﬁcacy of platelets
in promoting T cell-mediated responses (Iannacone et al., 2005).
Intravital microscopy studies also demonstrated the ability of acti-
vated platelets to restore lymphocyte rolling on high endothelial
venules of peripheral lymph nodes in L-selectin deﬁcient mice
(Diacovo et al., 1996), thus reconstituting their susceptibility to a
cutaneous delayed-type hypersensitivity reaction, elicited by 2,4-
dinitroﬂuorobenzene (Diacovo et al., 1998; Ludwig et al., 2010).
This platelet-assisted interaction between lymphocytes and vessel
walls seems to involve both B and T lymphocytes, including mem-
ory T cells, and can thus play a role in themaintenance of sustained
inﬂammation (Diacovo et al., 1996). Moreover a selective ability of
T-helper 1 lymphocytes (Th1) to interact with P-selectin has been
described in the T cell subset (Austrup et al., 1997), suggesting that
platelets could actively regulate the characteristics of the immune
inﬁltrate during chronic inﬂammation. Circulating platelets are
also armed with a large array of other immune signaling quanta
[e.g., the alarmin HighMobility Group 1 protein (HMGB1), IL1β,
and many chemokines], as well as defensive mediators (the so-
called thrombocidins), which exert direct killing actions against
invading bacteria (Yeaman, 2010; Semple et al., 2011). Further-
more platelets store large amounts of growth factors like PDGF,
VEGF,andTGFβ and,when recruited“at sites of inﬂammation and
vessel injury through hemostatic mechanisms” (Nurden, 2011),
platelets are able to release them and affect local tissue tropism
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(Nurden, 2011). The sprouting of new-vessels and the activation
of ﬁbroblasts within injured tissues or vessels are part of a physi-
ological response, which has the “aim” of preventing hemorrhage
and excessive exposure of the body to the hostile outside envi-
ronment (Maugeri et al., 2009). However, when these remodeling
responses occur constitutively in the absence of an injuring stimu-
lus, as in the case of atherosclerosis (Mullenix et al., 2005) or large
vessel vasculitides (Maugeri et al., 2009), the integrity and the con-
ductive performances of vessel are impaired (eventually leading
to ischemia or vessel disruption and hemorrhage; Maugeri et al.,
2009). Similarly substitution of functional tissueswith amorphous
ﬁbrosis (as happens in post-ischemic conditions during myocar-
dial infarction and stroke) eventually impairs the whole organ
function.
CHARACTERISTIC FEATURES OF SYSTEMIC SCLEROSIS
Systemic sclerosis (SSc) is an autoimmune disease, in which
excessive connective tissue deposition, inﬂammation and autoim-
munity and vascular dysfunction (the three main pathophysio-
logical hallmarks of the disease), rise from a largely unknown
pathogenic background. The clinical fallout of such complex
pathophysiological phenomena consists in a large spectrum of
clinical manifestations, characterized by failure of multiple organs
(including lung, kidney, heart, gastrointestinal tract, and skin), due
to ischemia or to the impairment of motility or substance exchange
with the environment after substitution of functional tissues with
amorphous ﬁbrotic tissue. Due to the scarcity of effective therapies
and to the frequent involvement of major organs, SSc signiﬁcantly
impacts on the patients quality of life and is associated with higher
overall mortality (Pattanaik et al., 2011).
Signs of systemic inﬂammation and autoimmunity are
detectable in almost all patients with SSc and comprise the activa-
tion of cellular andhumoral aswell as innate and adaptive immune
responses (Kahaleh and LeRoy, 1999; Postlethwaite and Chiang,
2007; Yoshizaki et al., 2009; Pattanaik et al., 2011). A characteristic
antiviral-like interferon-mediated response has been recognized
in patients with SSc (Lafyatis and York, 2009) and constitutes a
shared pathogenic hallmark of many connective tissue diseases
(Banchereau and Pascual, 2006). Marked signs of humoral innate
immunity activation are also detectable in SSc both in circulat-
ing blood (Yoshizaki et al., 2009) and affected tissues (Luchetti
et al., 2004; see also below), and have been shown to correlate
with disease activity (Yoshizaki et al., 2009). On the other hand
extensive antibody and cellular autoimmunity against vessel and
connective tissue constituents is thought to directly contribute
to tissue damage, stimulate the development of aberrant misre-
pair responses (Pattanaik et al., 2011) and enhance the activation
of innate immune players (including platelets; Postlethwaite and
Chiang, 2007).
Vascular impairment is one of the main and early appearing
hallmarks of SSc and develops as a consequence of the concur-
rent action of autoimmune reactions against vessel walls (Holt
et al., 1989; Kahaleh and Fan, 1997), endothelial dysfunction (with
prominent imbalance between vasoconstrictors and vasodilators;
Pattanaik et al., 2011), abnormalities in neural control of the vas-
cular tone (Freedman et al., 1999) and possibly alterations in
the hemostatic function. The development of ischemia, which
ultimately follows vascular impairment in SSc, leads to the release
of large amounts of active mitogens. These latter mediators of
cell proliferation, instead of initiating a physiological formation
of neo-vessels, give rise to aberrant and unfunctional neoangio-
genic responses (see below) and further stimulate ﬁbrogenesis
(Trojanowska, 2008; Pattanaik et al., 2011).
Fibrosis arises as a consequence of uncontrolled proliferation
and secretive activity of ﬁbroblasts, due to intense stimulation
by immune cells and ischemic tissue on a likely already abnor-
mal genetic background (Gardner et al., 2006). In tissue affected
by SSc ﬁbroblasts proliferate from resident precursors, trans-
differentiating cells or bone marrow-derived precursors (Frid
et al., 2002). Beside the functional and structural damage due to
the substitution of normal tissues with collagen and other gly-
coproteins, contraction of the ﬁbrotic tissue due to the activity
of a particular subtype of ﬁbroblasts (i.e., the myoﬁbroblasts)
ultimately worsen tissue ischemia and organ dysfunction.
PLATELET ACTIVATION AND PATHOGENESIS OF SSc
ACTIVATION OF PLATELETS IN SSc
Enhanced activation of platelets and increased tendency to aggre-
gation have long been observed in SSc patients (Kahaleh et al.,
1982; Goodﬁeld et al., 1993) and are generally attributed to the
concomitant dysfunction of the endothelium (Pattanaik et al.,
2011). Moreover the elevation of markers of platelet activation
like the HMGB1 or P-selectin has been shown to correlate with
disease activity in SSc (Agache et al., 2007; Yoshizaki et al., 2009),
as well as in other diseases characterized by prominent vascular
inﬂammation (Harris et al., 2012).
Several studies have revealed an increased responsiveness of
SSc platelets to 5-hydroxytryptamine (5HT), adrenaline,ADP, and
collagen (Friedhoff et al., 1984; Goodﬁeld et al., 1988; Postleth-
waite and Chiang, 2007). More recently SSc platelets were shown
to upregulate a speciﬁc non-integrin receptor for type I colla-
gen (Chiang et al., 2006). Type I collagen is in turn abundantly
expressed in (injured) vessel walls and is one of the main
constituent of ﬁbrotic tissues in SSc. Overexpression of the
non-integrin receptor for collagen I togetherwith enhanceddown-
stream signaling ultimately leads to further pro-coagulant activa-
tion of platelets, which undergo extensive cytoskeletal remodeling
and mobilization of intracellular calcium (Postlethwaite and
Chiang, 2007; Figure 1).
LUNGS, PLATELETS, AND SSc-PATHOGENESIS
The involvement of the lung is the leading cause of mortality
in SSc (Steen and Medsger, 2007). Pulmonary disease usu-
ally encompasses interstitial lung disease and pulmonary arterial
hypertension and it is clinically evident as progressive respiratory
insufﬁciency. Moreover histologic evidence of lung injury can be
detected in up to 80% of patients with SSc (D’Angelo et al., 1969).
In fact as the lung vasculature is the main portal system in the
body, it is highly exposed to the activity of circulating inﬂamma-
tory humoral and cellularmediators (including platelets) and thus
it constitutes the ideal setting for the complete expression of some
of the most characteristic pathogenic features of SSc, i.e., vascular
dysfunction and subsequent aberrant vessel and tissue remodeling.
Moreover, as suggested by the pathogenesis of transfusion-related
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FIGURE 1 | Involvement of platelets in the pathogenesis of SSc. Platelets
are stimulated by the injured endothelium and contribute to vascular
dysfunction and ischemia by participating in thrombotic events and by
releasing vaso-active moieties (such asTXA2). Increased expression of type I
collagen as a consequence of tissue ﬁbrosis further enhances platelet
activation. On the other hand platelets actively stimulate tissue ﬁbrosis by
releasing ﬁbrogenic mediators such as PDGF, TGF-β, lysophospholipids, and
serotonin. The interactions of platelets with immune cells in SSc are less
clearly understood. Platelets are known sources of active pro-inﬂammatory
mediators like HMGB1, and interestingly increased circulating levels of this
prototypic alarmin have been shown to correlate with disease activity in SSc.
Moreover evidence is growing about the prominent role of circulating
heterotypic aggregates (between platelets and innate immune cells) in the
pathogenesis of inﬂammatory and vascular diseases and recent studies are
currently evaluating their impact in the pathogenesis of SSc. Furthermore
other studies suggested the existence of a speciﬁc network between
collagen-reactive T lymphocyte and platelets in SSc. In this latter setting
platelet activation would be enhanced by the release of IFNγ and a wider
array of cytokines from autoreactive T lymphocyte, which in turn would affect
megakaryocyte maturation and platelet basal activation state.
acute lung injury (TRALI; Nurden, 2011), by clinical reports of
non-SSc interstitial lung disease after the onset of severe idio-
pathic thrombocytopenic purpura (ITP; Fontana et al., 2007) and
ﬁnally by detection of platelet activation markers in bronchoalve-
olar lavages of SSc patients with active pulmonary involvement
(Kowal-Bielecka et al., 2005), lungs constitute a preferential target
for platelet-induced inﬂammatory injury.
Lungs have long been recognized as secondary sites of throm-
bocytopoiesis (Kosaki, 2005). Differently from the bone marrow
(which is mainly constituted by immature immune cells and is
protected by the blood–marrow barrier), in the setting of the lung
megakaryocytes are potentially exposed to powerful inﬂamma-
tory stimuli, provided by resident or circulating mature immune
cells, such as lymphocytes (Kosaki, 2005; Postlethwaite and Chi-
ang, 2007; Nurden, 2011). A recent series of studies suggested
that autoreactive T lymphocytes, directed against collagen I,
could stimulate platelets through speciﬁc patterns of cytokines
and induce them to increase their own response to collagen I
and enhance their aggregation activity (Postlethwaite and Chiang,
2007). Although the precise way by which innate immune players
(as platelets are) could elicit a selective activation against a single
autoantigen in response to signals from adaptive immunity is still
incompletely clear, this kind of evidence provides an interesting
clue toward a better comprehension of the links between platelets
abnormalities and autoimmunity.
Activated or destructed platelets are known to release large
amounts of bioactive compounds in the bloodstream, most of
which are actively metabolized by the lungs, which are thus chron-
ically exposed to platelet-derived endogenous toxins. In particular
the lungs are the main physiologic ﬁlters for circulating 5HT, a
known marker of platelet activation and a key player in platelet
aggregation (Nurden, 2011), whose aberrant activity in tissue and
vessel remodeling is well-demonstrated by carcinoid heart disease
(Palaniswamy et al., 2012). Excessive circulating 5HT and defec-
tive platelet content (i.e., increased release of 5HT by platelets) has
been observed in patients with SSc (Klimiuk et al., 1989) and other
connective tissue diseases (Biondi et al., 1988; maybe account-
ing for the presence of mild to severe pulmonary involvement
in systemic lupus erythematosus or inﬂammatory myopathies).
Moreover platelet-derived serotonin has recently been linked to
the development of ﬁbrosis (Dees et al., 2011; see below). Along
with this line inhibition of platelet loading with 5HT by the
administration of selective serotonin reuptake inhibitors (SSRI)
has been proposed as a possible therapeutic option to face the
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presence of extensive ﬁbrogenic activity and vasoconstriction as
well as increased incidence of mood disorders in SSc (Coleiro
et al., 2001; Garcia-Porrua et al., 2004).
An imbalance between endothelial prostacyclin (PGI2) and
platelet-derived thromboxane (TXA2) has long been recognized as
a key factor in determining the risk of ischemia bymeans of platelet
aggregation and vessel vasoconstriction (and it constitutes the
main rationale for the use of low-dose aspirin for anti-thrombotic
prevention). Diffuse microvascular dysfunction with sustained
vasoconstriction, due to defective synthesis of PGI2, is a character-
istic feature of SSc lungs (Tuder et al., 1999) and accounts for the
frequent development of pulmonary hypertension and the efﬁcacy
of prostaglandins analogs like iloprost (Herrick, 2011). Moreover
this deﬁcit in prostacyclin activity likely promotes platelets aggre-
gation by acting synergistically with the known resistance of SSc
platelets to PGI2 signaling (Belch et al., 1985) and the enhanced
production of TXA2, due to collagen stimulation (Postlethwaite
and Chiang, 2007; Figure 1). Accordingly the use of prostacy-
clin analogs as well as other vasodilators has been suggested to
affect and improve also platelet function (Candela et al., 2001;
Herrick, 2011).
KIDNEYS, PLATELETS, AND THROMBOTIC MICROANGIOPATHY
Kidney disease in SScmanifests itself as the so-called“scleroderma
renal crisis,” the leading cause of death by SSc before the introduc-
tion of angiotensin converting enzyme inhibitors (ACEi; Steen and
Medsger, 2007). Although the hallmark of renal injury in SSc is
the aberrant activation of the renin–angiotensin–aldosterone sys-
tem, the initial sequence of vasoconstriction and ischemia (which
gives rise to a vicious circle, broken by the administration of ACEi)
appears to be primed bymicroangiopathic processes (Trostle et al.,
1988) similar to those seen in other SSc-vessels (and characterized
by deposition of platelet antigens within the vessel walls (Miller
et al., 1980). These processes, which lead to the development of
schistocytosis, thrombocytopenia, renal insufﬁciency, proteinuria
and an active urinary sediment, also resemble the pathophysio-
logical features of thrombotic thrombocytopenic purpura (TTP),
from which scleroderma renal crisis is often hardly distinguish-
able. Platelet consumption due to defective vonWillebrand factor
(vWF) turnover is the hallmark of TTP, but notably the presence
of “supranormal” multimers of vWF has also been recognized in
sera from SSc patients (Mannucci et al., 1989).
PLATELETS AND ABNORMALITIES OF CELL PROLIFERATION
AND SECRETION IN SSc
Aberration in cell proliferation and secretion is a hallmark of
SSc and expresses on the one hand as “frustrated angiogenesis,”
a process ultimately leading to chronic ischemia, and on the other
hand as excessive myoﬁbroblast proliferation and deposition of
connective tissue. Such anomalies in the control of the cell life-
cycle are globally due to excessive release of mitogens like TGF-β,
PDGF, VEGF, FGF, IGF1, endothelin 1, IL6, IL4, and IL13 in
response to inﬂammation and/or ischemic injury (Mauviel, 2005;
Trojanowska, 2008). The importance of these molecules in the
pathogenesis of SSc has been conﬁrmed recently by studies utiliz-
ing DNA microarray technologies (Whitﬁeld et al., 2003; Gardner
et al., 2006). However such kind of studies can only suggest the
nature of the complex intercellular interactions underlying the
development of such humoral alterations and may even fail to
adequately evaluate subtle functional variations in the biological
behavior of cytoplasts containing small amounts of RNA, as are
platelets (Postlethwaite and Chiang, 2007).
Several other studies have indeed recognized the fundamental
role of platelets in determining tissue remodeling in SSc (Silveri
et al., 2001) as in many other diseases related to vascular injury
(May et al., 2002; Donners et al., 2008; Nurden, 2011; Maugeri
et al., 2012):
(1) as the main constituents of blood clots, platelets are directly
responsible for the development of ischemia by means of
(micro)-vascular thrombosis;
(2) by their productive interactions with leukocytes (Maugeri
et al., 2012), they actively drive the subsequent inﬂammatory
and (mis)-repair response (Figure 1);
(3) in the setting of injured vessels, they also directly release active
mitogens like TGF-β, PDGF, or lysophospholipids (Pattanaik
et al., 2011) and stimulate ﬁbroblasts sensitivity by releasing
serotonin (Dees et al., 2011; Figure 1);
Defective vasculogenesis characterize SSc (Kuwana et al., 2004)
and develops as a consequence of the overwhelming activity of
anti-angiogenic factors such as the long pentraxin PTX3 (which
is released by the endothelium and by activated myoﬁbroblasts
in SSc; Luchetti et al., 2004; Margheri et al., 2010) upon a yet
enhancedVEGF/FGF-mediated angiogenic response (Giusti et al.,
2006; Margheri et al., 2010), which shows the important contri-
bution of circulating platelets (Solanilla et al., 2009). PTX3, an
emerging marker and a central player in vascular/inﬂammatory
injury (Bottazzi et al., 2010; Maugeri et al., 2012), besides its
widespread regulatory functions in innate immunity (Manfredi
et al., 2008), acts in the circulating blood as a key modulator
of neutrophil-platelet cross-talk: after release by neutrophil sec-
ondary granules PTX3 inhibits platelet–leukocyte aggregation and
prevents the binding of ﬁbrinogen to activated platelets (Maugeri
et al., 2012). Less is known about the role of tissue-derived PTX3
on platelets, especially in the setting of SSc.
CONCLUSION
Besides their ancient role in hemostasis, platelets exert a complex
set of interactions with circulating and tissue residing cells, which
connotes them as circulating regulators of vascular homeostasis,
immune function, and tissue remodeling. Alongwith this line they
are actively involved in the development of the main pathological
phenomenaof SSc, although variations in their biological behavior
are probably underestimatedmarkers of disease activity and treat-
ment response to date. Further researches about the involvement
of platelets in the initiation ad perpetuation of the pathogenic
phenomena of SSc would possibly disclose new therapeutic
perspectives for such a nebulous and still health-impacting disease.
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